Anika Therapeutics (NASDAQ: ANIK) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Valuation and Earnings

This table compares Anika Therapeutics and Syros Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Anika Therapeutics $111.36 million 6.99 $56.02 million $2.26 23.49
Syros Pharmaceuticals $1.42 million 371.52 -$48.99 million ($2.13) -9.43

Anika Therapeutics has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

84.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 59.6% of Syros Pharmaceuticals shares are held by institutional investors. 6.6% of Anika Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Anika Therapeutics and Syros Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anika Therapeutics 0 0 0 0 N/A
Syros Pharmaceuticals 0 2 5 0 2.71

Syros Pharmaceuticals has a consensus price target of $21.77, suggesting a potential upside of 8.35%. Given Syros Pharmaceuticals’ higher possible upside, analysts plainly believe Syros Pharmaceuticals is more favorable than Anika Therapeutics.

Volatility & Risk

Anika Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of -4.02, suggesting that its share price is 502% less volatile than the S&P 500.

Profitability

This table compares Anika Therapeutics and Syros Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Anika Therapeutics 30.44% 14.88% 13.78%
Syros Pharmaceuticals N/A -60.15% -54.25%

Summary

Anika Therapeutics beats Syros Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company’s therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company’s ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.